252873-35-1

Usage

Uses

Used in Pharmaceutical Industry:
(3R,3αS,6αR)-Hexahydrofuro[2,3-β]furan-3-yl-4-nitrophenyl carbonate is used as a potential pharmaceutical compound for its unique molecular structure, which may offer novel therapeutic properties. Its furofuran ring, nitrophenyl group, and carbonate functional group could contribute to the development of new drugs with specific targeting or activity profiles.
Used in Materials Science:
In the field of materials science, (3R,3αS,6αR)-Hexahydrofuro[2,3-β]furan-3-yl-4-nitrophenyl carbonate may be utilized as a component in the synthesis of new materials with unique properties. Its structural features could be leveraged to create materials with enhanced performance characteristics, such as improved stability, reactivity, or selectivity in various applications.
Note: The specific applications mentioned above are hypothetical and provided as examples based on the compound's structural features. Further research and development would be necessary to validate these potential uses.

Upstream product

• 7693-46-1 4-Nitrophenyl chloroformate 
• 156928-09-5 (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol 
• 109789-19-7 (3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol 
• 109789-18-6 (2aRS,3aSR)-hexahydrofuro[2,3-b]furan-3-one 
• 5070-13-3 bis-(p-nitrophenyl) carbonate 
• 156928-10-8 (3S,3aR,6aS)-3-hydroxyhexahydrofuro<2,3-b>furan 
• 109789-19-7 hexahydrofuro[2,3-b]furan-3-ol 
• 96406-00-7 (4,5-Dihydro-3-furanyl)glyoxylsaeure-ethylester 
• 1378929-89-5 ethyl 2-(3-bromo-2-ethoxytetrahydrofuran-3-yl)-2-oxoacetate 
• 1378929-91-9 ethyl 2-(2-ethoxy-tetrahydrofuran-3-yl)-2-oxoacetate 
• 640289-34-5 hexahydrofuro[2,3-b]furan-3-yl acetate 
• 162119-35-9 3-acetoxy-(3R,3αS,6αR)-bis-tetrahydrofuran 
• 58399-67-0 (3aR,4S,6aR)-4-(hydroxymethyl)tetrahydrofuro[3,4-b]furan-2(3H)-one 
• 80923-96-2 ((3aR,4S,6aR)-2-oxohexahydrofuro[3,4-b]furan-4-yl)methyl benzoate 

Downstream Products

• 206361-99-1 darunavir 
• 206361-99-1 darunavir 
• 186487-59-2 {(1S,3S,4S)-1-Benzyl-4-[(3S,3aR,6aS)-(hexahydro-furo[2,3-b]furan-3-yl)oxycarbonylamino]-3-hydroxy-5-phenyl-pentyl}-carbamic acid tert-butyl ester 
• 622866-41-5 trifluoromethanesulfonic acid 4-(2S,3R)-{2-([2R,3S]-hexahydro-furo[2,3-b]furan-(3R)-3-yloxycarbonylamino)-3-hydroxy-4-[N-isobutyl-(N-methoxybenzenesulfonyl)-amino]-butyl}-phenyl ester 
• 622866-42-6 {(1S,2R)-[1-(4-formyl-benzyl)]-(2R)-2-hydroxy-3-[N-isobutyl-(N-4-methoxy-benzenesulfonyl)-amino]-propyl}-carbamic acid [3R,3aS,6aR]-hexahydrofuro[2,3-b]furan-3-yl ester 
• 605654-10-2 {[1S,2R]-2-hydroxy-1-(4-hydroxy-benzyl)-3-[N-isobutyl-(N-4-methoxybenzenesulfonyl)-amino]-propyl}-carbamic acid hexahydro-[3R,3aS,6aR]-furo[2,3-b]furan-3-yl ester 
• 186487-62-7 {(1S,3S,4S)-1-Benzyl-4-[(3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl)oxycarbonylamino]-3-hydroxy-5-phenyl-pentyl}-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

The Chiron Approach to (3 R,3 aS,6 aR)-Hexahydrofuro[2,3- b]furan-3-ol, a Key Subunit of HIV-1 Protease Inhibitor Drug, Darunavir

We describe an enantioselective synthesis of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol which is a key subunit of darunavir, a widely used HIV-1 protease inhibitor drug for the treatment of HIV/AIDS patients. The synthesis was achieved in optically pure form utilizing commercially available sugar derivatives as the starting material. The key steps involve a highly stereoselective substrate-controlled hydrogenation, a Lewis acid catalyzed anomeric reduction of a 1,2-O-isopropylidene-protected glycofuranoside, and a Baeyer-Villiger oxidation of a tetrahydrofuranyl-2-aldehyde derivative. This optically active ligand alcohol was converted to darunavir efficiently.

Crystalline Darunavir

The present invention relates to a non-solvated crystalline Darunavir, process for its preparation and pharmaceutical composition comprising it. The present invention also relates to a process for the preparation of amorphous Darunavir from a non-solvated crystalline Darunavir.

PROCESS FOR THE PREPARATION OF SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS

The present invention relates to a process for the preparation of sulfonamides useful as retroviral protease inhibitors.

Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance

Summary The rapid evolution of HIV under selective drug pressure has led to multidrug resistant (MDR) strains that evade standard therapies. We designed highly potent HIV-1 protease inhibitors (PIs) using the substrate envelope model, which confines inhib

CRYSTALLINE DARUNAVIR

The present invention relates to a non-solvated crystalline Darunavir, process for its preparation and pharmaceutical composition comprising it. The present invention also relates to a process for the preparation of amorphous Darunavir from a non-solvated crystalline Darunavir.

HIV protease inhibiting compounds

A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

Research and development of an efficient synthesis of hexahydrofuro[2,3-b] furan-3-ol moiety - a key component of the HIV protease inhibitor candidates

A highly efficient method for synthesizing racemic hexahydrofuro[2,3-b] furan-3-ol has been developed utilizing a lanthanide catalyst, such as Yh(fod)3, to promote condensation of 23-dihydrofuran and glycolaldehyde dimer. Access to either optically enriched enantiomer of bisfuran alcohol can be obtained by using this method employing chiral ligands with the lanthanide catalyst In support of Gilead Sciences' protease inhibitor project, this method has been demonstrated to be a robust and scalable process with potential application for the construction of a variety of furo[2,3-b]furan derivatives.

PROCESS FOR PREPARATION OF HIV PROTEASE INHIBITORS

A process for the synthesis of bisfuran intermediates useful for preparing antiviral HIV protease inhibitor compounds is hereby disclosed.

HIV protease inhibiting compounds

A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles

A novel series of tyrosine-derived HIV protease inhibitors was synthesized and evaluated for in vitro antiviral activity against wild-type virus and two protease inhibitor-resistant viruses. All of the compounds had wild-type antiviral activities that were similar to or greater than several currently marketed HIV protease inhibitors. In addition, a number of compounds in this series were more potent against the drug-resistant mutant viruses than they were against wild-type virus.